U.S. Physical Therapy, Inc. (USPH) Expected to Post Quarterly Sales of $107.18 Million

Wall Street brokerages expect U.S. Physical Therapy, Inc. (NYSE:USPH) to announce $107.18 million in sales for the current quarter, according to Zacks. Two analysts have made estimates for U.S. Physical Therapy’s earnings, with the lowest sales estimate coming in at $105.80 million and the highest estimate coming in at $108.56 million. U.S. Physical Therapy reported sales of $97.57 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 9.8%. The firm is expected to issue its next earnings report before the market opens on Thursday, May 3rd.

On average, analysts expect that U.S. Physical Therapy will report full-year sales of $443.12 million for the current financial year, with estimates ranging from $436.57 million to $449.67 million. For the next financial year, analysts forecast that the company will post sales of $468.10 million per share, with estimates ranging from $449.96 million to $486.23 million. Zacks’ sales averages are an average based on a survey of research firms that cover U.S. Physical Therapy.

U.S. Physical Therapy (NYSE:USPH) last issued its earnings results on Thursday, March 8th. The company reported $0.49 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.49. The firm had revenue of $109.20 million during the quarter, compared to the consensus estimate of $104.12 million. U.S. Physical Therapy had a return on equity of 13.12% and a net margin of 5.38%.

Several brokerages have commented on USPH. Cantor Fitzgerald boosted their target price on U.S. Physical Therapy to $90.00 and gave the stock an “overweight” rating in a research note on Friday, March 9th. Barrington Research reaffirmed a “hold” rating on shares of U.S. Physical Therapy in a research note on Friday, March 9th. Zacks Investment Research downgraded U.S. Physical Therapy from a “buy” rating to a “hold” rating in a research note on Friday, March 9th. ValuEngine raised U.S. Physical Therapy from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, Jefferies Group set a $76.00 price objective on U.S. Physical Therapy and gave the company a “hold” rating in a research note on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. U.S. Physical Therapy presently has a consensus rating of “Hold” and a consensus price target of $79.40.

In related news, COO Glenn Mcdowell sold 2,743 shares of the company’s stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $86.11, for a total value of $236,199.73. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Bernard A. Harris, Jr. sold 6,000 shares of the company’s stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $86.53, for a total value of $519,180.00. The disclosure for this sale can be found here. Insiders sold 18,643 shares of company stock valued at $1,583,645 in the last ninety days. 2.50% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the stock. Kings Point Capital Management boosted its holdings in U.S. Physical Therapy by 3.7% in the fourth quarter. Kings Point Capital Management now owns 28,096 shares of the company’s stock valued at $2,029,000 after acquiring an additional 1,000 shares during the last quarter. Bank of Montreal Can boosted its holdings in shares of U.S. Physical Therapy by 35.6% during the 4th quarter. Bank of Montreal Can now owns 4,535 shares of the company’s stock worth $327,000 after buying an additional 1,191 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of U.S. Physical Therapy by 48.6% in the 4th quarter. Envestnet Asset Management Inc. now owns 3,704 shares of the company’s stock worth $267,000 after purchasing an additional 1,212 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of U.S. Physical Therapy by 59.9% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,770 shares of the company’s stock worth $231,000 after purchasing an additional 1,412 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of U.S. Physical Therapy by 4.5% in the 4th quarter. Rhumbline Advisers now owns 42,560 shares of the company’s stock worth $3,073,000 after purchasing an additional 1,831 shares in the last quarter. Institutional investors and hedge funds own 96.60% of the company’s stock.

NYSE USPH remained flat at $$92.85 during trading on Wednesday. The company’s stock had a trading volume of 68,391 shares, compared to its average volume of 59,569. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.95 and a current ratio of 1.95. The firm has a market capitalization of $1,168.16, a P/E ratio of 44.85, a price-to-earnings-growth ratio of 3.39 and a beta of 1.08. U.S. Physical Therapy has a 12-month low of $56.50 and a 12-month high of $93.45.

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 13th. Stockholders of record on Wednesday, March 21st were paid a $0.23 dividend. The ex-dividend date of this dividend was Tuesday, March 20th. This represents a $0.92 annualized dividend and a dividend yield of 0.99%. This is an increase from U.S. Physical Therapy’s previous quarterly dividend of $0.20. U.S. Physical Therapy’s dividend payout ratio is currently 44.23%.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3377349/u-s-physical-therapy-inc-usph-expected-to-post-quarterly-sales-of-107-18-million.html.

U.S. Physical Therapy Company Profile

U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.

Get a free copy of the Zacks research report on U.S. Physical Therapy (USPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for U.S. Physical Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

ConocoPhillips  VP Glenda Mae Schwarz Sells 6,763 Shares
ConocoPhillips VP Glenda Mae Schwarz Sells 6,763 Shares
Editas Medicine  Insider Charles Albright Sells 10,000 Shares of Stock
Editas Medicine Insider Charles Albright Sells 10,000 Shares of Stock
Ekso Bionics  Director Steven Sherman Buys 200,000 Shares of Stock
Ekso Bionics Director Steven Sherman Buys 200,000 Shares of Stock
Shopify  Director Tobias Albin Lutke Sells 1,666 Shares of Stock
Shopify Director Tobias Albin Lutke Sells 1,666 Shares of Stock
Reviewing Argo Group  and Stewart Information Services
Reviewing Argo Group and Stewart Information Services
Analyzing Simulations Plus  & NetScout Systems
Analyzing Simulations Plus & NetScout Systems


© 2006-2018 Ticker Report. Google+.